Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Olympus To Step Up Endoscope Business In China

This article was originally published in PharmAsia News

Executive Summary

Top endoscope maker Olympus recently disclosed that its capsule endoscope is currently under review with China's State FDA and is expected to enter the China market as early as late this year. The capsule endoscope will represent a milestone product for the firm's health care business to open up China's market. Even though digital cameras and endoscopes make up one-third each of Olympus' business, the company is only known in China for its cameras. Thus, the firm's primary and most pressing task is to build up brand awareness in the country. To quickly occupy the market, Olympus has established main branches in Beijing, Shanghai and Guangzhou as well as a network of 31 representative offices across the country. It will next target gastroenterology and general surgery as two focus areas. (Click here for more - Chinese Language)

You may also be interested in...



TransEnterix Names New CFO, Reports Negative Q2 Earnings Amid Challenging Times

TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.

Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

CureVac Launches IPO, Adds To Big 2020 Cash Haul

CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel